U.S. markets closed
  • S&P 500

    3,911.74
    +116.01 (+3.06%)
     
  • Dow 30

    31,500.68
    +823.32 (+2.68%)
     
  • Nasdaq

    11,607.62
    +375.43 (+3.34%)
     
  • Russell 2000

    1,765.74
    +54.06 (+3.16%)
     
  • Crude Oil

    107.06
    +2.79 (+2.68%)
     
  • Gold

    1,828.10
    -1.70 (-0.09%)
     
  • Silver

    21.13
    +0.09 (+0.42%)
     
  • EUR/USD

    1.0559
    +0.0034 (+0.33%)
     
  • 10-Yr Bond

    3.1250
    +0.0570 (+1.86%)
     
  • GBP/USD

    1.2270
    +0.0009 (+0.07%)
     
  • USD/JPY

    135.2100
    +0.2770 (+0.21%)
     
  • BTC-USD

    21,402.90
    +7.14 (+0.03%)
     
  • CMC Crypto 200

    462.12
    +8.22 (+1.81%)
     
  • FTSE 100

    7,208.81
    +188.36 (+2.68%)
     
  • Nikkei 225

    26,491.97
    +320.72 (+1.23%)
     

Cliff Smith Joins PetVivo Holdings, Inc. as the Regional Sales Manager

  • Oops!
    Something went wrong.
    Please try again later.
·4 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
PetVivo Holdings, Inc.
PetVivo Holdings, Inc.

PetVivo Holdings, Inc.

Cliff Smith Joins PetVivo Holdings, Inc. as the Regional Sales Manager
Cliff Smith Joins PetVivo Holdings, Inc. as the Regional Sales Manager

MINNEAPOLIS, MN, US, March 08, 2022 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the "Company") an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals is pleased to announce that Cliff Smith has accepted a position with the Company as its new Regional Sales Manager for the Southeast Region of the United States.

"Cliff adds a key component to accomplishing our corporate goals related to sales and distribution of our revolutionary product Spryng with OsteoCushion technology. The focus on sales has become a key objective to the success of our Company and we believe the vast insight and expertise that Cliff brings to PetVivo puts us in an excellent position to meet this objective,” said John Lai, Chief Executive Officer of PetVivo Holdings, Inc. “Cliff is excellent in promoting and selling veterinary products. These skills will propel the sale of our veterinary medical device, Spryng, for use in companion animals."

Mr. Smith has more than 25 years of experience related to distribution and manufacturing of veterinary products in the Southeast region of the United States. He began his career working for the Hunt family in their cattle and cutting horse operations, which transitioned to training, breeding and racing thoroughbred horses. Mr. Smith next advanced his career to veterinary product distribution by taking a position with Milburn Distributions where he remained for approximately twenty years and assisted in growing Milburn to one of the largest equine veterinary distribution companies in the world. In 2017, he began working as a consultant for numerous veterinary products companies commercializing products and equipment with a focus on equine and mixed animal. Mr. Smith graduated from Texas A&M, class of 1981, where he completed a Bachelor of Science degree in Agricultural Economics.

“I am incredibly excited to join the PetVivo sales and marketing team. PetVivo’s technology has tremendous potential to enhance the lives of companion animals and their owners,” said Mr. Smith. “I am looking forward to joining a company that possesses a ground-breaking technology and has the ability to grow the market with a product that has been shown to improve the medical outcomes of animals.”

For more information about PetVivo Holdings, Inc. and its innovative product, Spryng, please contact info1@petvivo.com or visit https://petvivo.com/ and https://sprynghealth.com/

About PetVivo Holdings, Inc.

PetVivo Holdings Inc. (NASDAQ: PETV) is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The Company's strategy is to leverage human therapies for the treatment of companion animals in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics.

PetVivo has a pipeline of seventeen products for the treatment of animals and people. A portfolio of nineteen patents protects the Company's biomaterials, products, production processes and methods of use. The Company’s lead product SPRYNG, a veterinarian-administered, intraarticular injection for the treatment of lameness and other joint related afflictions, including osteoarthritis, in dogs and horses, is currently available for commercial sale to veterinarians.

CONTACT:

John Lai, CEO
PetVivo Holdings, Inc.
Email: info1@petvivo.com
(952) 405-6216

Forward-Looking commercial Statements:

The foregoing material may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company’s proposed development and commercial timelines, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements, including the potential listing of the Company’s common stock on Nasdaq, are based on information currently available the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning the Company’s business are described in detail in the Company’s Annual Report on Form 10-K for the year ended March 31, 2021 and other periodic and current reports filed with the Securities and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

Attachment